Liver fibrosis and adverse outcomes in COVID-19

Abstract

Recently, an interesting study entitled “Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19” was published in Digestive and Liver Disease [1]. In this retrospective cohort study, the authors explored the relationship between liver fibrosis and poor prognosis in patients with coronavirus disease (COVID-19). After controlling for potential confounding factors, the authors found that the presence of liver fibrosis was associated with higher mechanical ventilation, acute kidney injury (AKI), and mortality.